BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lincoln Plant Problems Continue to Dog Novartis AG (NVS)


1/24/2013 8:04:39 AM

Though some limited production has resumed at the Novartis plant east of Lincoln, the ongoing problems there continue to drag down earnings for the company's consumer health division. Julie Masow, a Novartis spokeswoman, said Tuesday the plant east of Lincoln has resumed limited production of "select Animal Health and OTC (over-the-counter) products." She declined to disclose specific brand names. Novartis said Wednesday in releasing its 2012 fourth-quarter and full-year financial results that it has engaged third-party manufacturers to produce Excedrin Migraine, Triaminic and Lamisil AT products. The company also said it will be shipping Excedrin Extra Strength products to some customers this month. Despite getting some of its over-the-counter production restarted, the ongoing issues at the Lincoln plant continue to weigh on Novartis's bottom line. The Lincoln plant shut down in December 2011. Inspections by the Food and Drug Administration highlighted numerous problems with cross-contamination of drugs and a lack of attention to the problems by management at the plant. The company said in its earnings news release that the consumer health division, which includes over-the-counter drugs and animal health products, had an 11 percent decline in sales in the fourth quarter compared with a year ago and a 19 percent drop in 2012 compared with 2011.

Read at Journal Star

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES